Last reviewed · How we verify

Cataflam® 50 coated tablet

Ain Shams University · FDA-approved active Small molecule Quality 2/100

Cataflam® 50 coated tablet is a Small molecule drug developed by Ain Shams University. It is currently FDA-approved.

At a glance

Generic nameCataflam® 50 coated tablet
SponsorAin Shams University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cataflam® 50 coated tablet

What is Cataflam® 50 coated tablet?

Cataflam® 50 coated tablet is a Small molecule drug developed by Ain Shams University.

Who makes Cataflam® 50 coated tablet?

Cataflam® 50 coated tablet is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

What development phase is Cataflam® 50 coated tablet in?

Cataflam® 50 coated tablet is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing